{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-019884","form_type":"8-K/A","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2025-07-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.405453+00:00","generated_at":"2026-05-18T06:19:18.168879+00:00","sec_items":["9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Biofrontera to acquire US Ameluz/RhodoLED rights; royalty 12-15%, 10% equity stake","bullets":["Upfront EUR 2,593,750 payment due June 30, 2025; condition to raise $8.5M preferred equity by same date.","Royalty on US net sales: 12% up to $65M revenue, 15% above; minimum 80,000 tubes/year penalty clause.","Sellers receive preferred stock convertible to 10% of fully diluted Biofrontera Inc. common equity.","Sellers get 1-2 board seats as long as they hold preferred stock; term sheet void if conditions unmet.","Buyer assumes all US supply costs and legal defense; stockholder vote required for conversion rights."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-019884","json":"https://secwatch.observer/filing/0001641172-25-019884.json","markdown":"https://secwatch.observer/filing/0001641172-25-019884.md","text":"https://secwatch.observer/filing/0001641172-25-019884.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000164117225019884/0001641172-25-019884-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000164117225019884/form8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:19:18.168879+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}